Researchers Identify a Mechanism that Stops Progression of Abnormal Cells into Cancer

Researchers from Boston University School of Medicine (BUSM) report that a tumor suppressor pathway, called the Hippo pathway, is responsible for sensing abnormal chromosome numbers in cells and triggering cell cycle arrest, thus preventing progression into cancer. Although the link between abnormal cells and tumor suppressor pathways—like that mediated by the well known p53 gene—has […]

Tagged:

A Gene That May Increase Alzheimer’s Disease Risk in African-Americans

Researchers from Boston University School of Medicine (BUSM) report that two rare variants in the AKAP9 gene significantly increase the risk of Alzheimer’s disease (AD) in African-Americans. This previously unknown association furthers the understanding of the role of genetic factors in the development of AD, according to the researchers, whose findings appear in Alzheimer’s & […]

Tagged: ,

Saying Goodbye to BU’s Former “First Lady”

Jasmine Chobanian remembered as a patron of the arts and a humanitarian. Jasmine Chobanian, who was regarded as the “First Lady” of Boston University during the many years that her husband Aram V. Chobanian, MD, served in University leadership, both as dean of the School of Medicine and the ninth president of Boston University (2003–2005), […]

Dr. Domenic Ciraulo Appointed Chairman of NIAAA Review Group

BUSM’s Domenic A. Ciraulo, MD, was appointed as the chairman of the National Institute of Alcohol Abuse and Alcoholism (NIAAA) study section AA-3, which reviews all grant applications requesting funding for clinical studies of treatments for alcoholism and health services research on alcoholism. He has been funded by NIAAA for more than 18 years, serving […]

Researchers Identify Potential Biomarker for Alzheimer’s

Researchers from Boston University School of Medicine (BUSM) report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer’s disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically. These findings appear in the Annals of Neurology. AD is the most […]

Tagged: